Effective Microorgainsm (EM) Fermentation Extract Attenuates Airway Hyperreactivity and Lung Inflammation In A Mouse Model of Asthma.
- Author:
Jeong Su DO
1
;
Youn Hwa CHOI
;
Hyo Jung SEO
;
Jae Hwan RYOO
;
Sang Yun NAM
Author Information
- Publication Type:Original Article
- Keywords: Effective microorganisms; Airway hyperreactivity; Inflammation; Eosinophils; Cytokine
- MeSH: Administration, Oral; Animals; Asthma*; Bronchoalveolar Lavage Fluid; Eosinophils; Fermentation*; Immunoglobulin E; Immunoglobulin G; Inflammation; Interleukin-13; Interleukin-4; Interleukin-5; Leukocytes; Lung*; Lymph Nodes; Mice*; Ovum; Pneumonia*; Th2 Cells
- From:Journal of Bacteriology and Virology 2006;36(1):1-10
- CountryRepublic of Korea
- Language:English
- Abstract: Effective microorganism (EM) fermentation extract has been widely used for agricultural and environmental application. It has been recently revealed that EM cocktail treatment may be effective for treatment of diseases including cancer. In the present study, effectiveness of EM cocktail to control asthma was investigated using a mouse model of allergic asthma. Asthmatic mice sensitized and intranasally challenged with OVA were orally given EM fermentate (EM-1(R) during antigen challenge. Administration of EM-1(R) resulted in a significant reduction in airway hyper-reactivity (AHR) and airway recruitment of total leukocytes and eosinophils. Cytokine (IL-4, IL-5 and IFNgamma) levels in bronchoalveolar lavage fluid (BALF) and lung tissues were not altered by EM-1(R) treatment. However, IL-13 level in BALF was considerably lower in EM-1(R) treated mice than in controls. Moreover, Ag-specific IL-4, IL-5 and IL-13 production of draining lymph node cells were markedly downregulated by EM-1(R) treatment when compared to controls, whereas their IFNgamma production was not significantly different. Those data show that EM-1(R) treatment suppresses type 2 helper T (Th2), but not type 1 helper T (Th1), cell response. This finding was also supported by serum antibody data showing that IgE and IgG1 levels in EM-1(R) treated mice were significantly lower than in controls, while IgG2a level was not significantly different between two groups. In conclusion, oral administration of EM-1(R) attenuates asthmatic manifestations including AHR and airway recruitment of eosinophils in a mouse model and which possibly results from selective inhibition of Th2 cell response to allergen. Our data also suggest that EM-1(R) may be effectively applied for control of allergic asthma.
